A Phase 3 interventional study of Pegylated liposomal doxorubicin (SCH 200746) and Capecitabine in Breast Cancer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-08.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.
Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one is the 10th largest by enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2006, is one of 10 in phase 3, and was the 11th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70
SCRI Development Innovations, LLC · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
Shanghai Pudong Hospital · Sites in China
Ages 18–70 · Women only
National Taiwan University Hospital · Sites in Taiwan
Ages 20+ · Women only
By country, each count listing its studies:
liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 42 · Phase 3 10 · Phase 4 6
First in 2000; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 57 across the 66 interventional studies. Of the 40 that completed or were terminated, 18 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 67 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
41 studies in Breast Neoplasms by Merck & Co., Inc: 5 open now, 8 under way, 5 of them phase 3. Of 31 finished, 16 (52%) have results posted.
Among the 41 studies in Breast Neoplasms by Merck & Co., Inc, this one is the 10th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2006, is one of 8 in phase 3, and was the 6th registered.
Merck & Co., Inc’s Breast Neoplasms studies by the year they started, since 2000.
2 of the studies testing liposomal doxorubicin in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03971409Laura Huppert, MD, BAAvelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | 2027-01-31 |
| NCT05748834SCRI Development Innovations, LLCStudy of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 41 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multinational, randomized, multicenter trial designed to compare pegylated liposomal doxorubicin with capecitabine as first line chemotherapy of metastatic breast cancer. The primary objective of the study is to compare the time to disease progression, although overall response rates, overall survival, quality of life, time to treatment failure, and safety and tolerability will also be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
hormonal therapy or chemotherapy in the setting; patients may have received hormonal therapy in metastatic setting, patients may have received local radiotherapy).
Patients with Human epidermal growth factor receptor 2 (Her-2/neu) overexpressing tumors with the most recent evaluation as the relevant result
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pegylated liposomal doxorubicin (SCH 200746)
Drug: Capecitabine
pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
Time to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST)
TTP was defined as the time from onset of treatment with study drug until first evidence/diagnosis of progressive disease or - in the absence of any diagnosis of progressive disease - until the participant´s death. Diagnosis of progressive disease was done according to RECIST (Version 1.0) and/or investigator assessment based on RECIST. RECIST criteria used changes in the largest diameter of target/non-target lesions. Target (measurable) lesions were up to a maximum of 5 per organ \& \>20 mm by clinical imaging (\>=10 mm with spiral CT scan). Non-target lesions were all other lesions.
Time frame: From Day 1 (Cycle 1) until First Evidence/Diagnosis of Progressive Disease or Death
Number of Participants With an Overall Response (Complete Response [CR] + Partial Response [PR]) Between PLD and Capecitabine Treatment Groups
Overall responses by investigator assessment/RECIST criteria of participant responses; CR=disappearance of target/nontarget lesions + PR=30% decrease in longest diameter sum (noting baseline sum) of target lesions. RECIST used changes in the largest diameter of target/non-target lesions. Target lesions were up to a maximum of 5 per organ \& \>20 mm by clinical imaging (\>=10 mm with spiral CT scan). Non-target lesions were all other lesions. Evaluation of progress was repeated every 3 months (+/-7 days) post first date of lesion measurements, in detection absence until the participant´s death.
Time frame: From Day 1 (Cycle 1) until First Evidence/Diagnosis of Progressive Disease or Death
Overall Survival Time in the PLD and Capecitabine Treatment Groups
Survival time was defined as duration time from onset of treatment with the study drug until death.
Time frame: From Day 1 (Cycle 1) until Death
Time to Treatment Failure in the PLD and the Capecitabine Treatment Groups
Time to treatment failure was defined as the duration of time from the date of the first administration of the study drug to the date of discontinuation of the study drug for any reason.
Time frame: From Day 1 (Cycle 1) until End of Treatment
Quality of Life (QoL) Measured by QoL Questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) + Subjective Significance Questionnaire (SSQ))
QoL questionnaire was an EORTC QLQ-C30 \& SSQ integration. Scores on the SSQ scale ranged from 1 (very much worse) - 7 (very much better). SSQ consisted of 4 items which corresponded to core domains in the 30 Item EORTC QLQ-C30, such as improvement/deterioration in physical functioning, emotional functioning, social functioning, global QoL. Percentages were based on number of participants at each cycle \& rounded to the nearest whole number. Early Withdrawal Questionnaires were obtained in 7-14 days of study drug final dose.
Time frame: From Screening to Day 1 of every Treatment Cycle up to 12 Cycles
210 participants were enrolled with 105 participants randomized for treatment with PLD and 105 participants randomized for treatment with Capecitabine, of which 7 participants in the PLD group and 3 participants in the Capecitabine group were not treated.
| Milestone | Pegylated Liposomal Doxorubicin (PLD) | Capecitabine |
|---|---|---|
| Started | 98 | 102 |
| Completed | 62 | 68 |
| Not completed | 36 | 34 |
TTP was defined as the time from onset of treatment with study drug until first evidence/diagnosis of progressive disease or - in the absence of any diagnosis of progressive disease - until the participant´s death. Diagnosis of progressive disease was done according to RECIST (Version 1.0) and/or investigator assessment based on RECIST. RECIST criteria used changes in the largest diameter of target/non-target lesions. Target (measurable) lesions were up to a maximum of 5 per organ \& \>20 mm by clinical imaging (\>=10 mm with spiral CT scan). Non-target lesions were all other lesions.
| Months | Pegylated Liposomal Doxorubicin (PLD) | Capecitabine |
|---|---|---|
| By Investigator Assessment (ITT) | 6.02 (5.10 to 8.19) | 6.05 (4.27 to 9.07) |
| By RECIST Criteria (ITT) | 6.58 (5.29 to 8.19) | 7.10 (4.77 to 9.53) |
| By Investigator Assessment (TTP N = 63, N = 59) | 5.85 (4.37 to 7.86) | 5.88 (2.99 to 8.98) |
| By RECIST Criteria (TTP N = 63, N = 59) | 6.02 (4.37 to 7.86) | 6.05 (4.08 to 9.27) |
Overall responses by investigator assessment/RECIST criteria of participant responses; CR=disappearance of target/nontarget lesions + PR=30% decrease in longest diameter sum (noting baseline sum) of target lesions. RECIST used changes in the largest diameter of target/non-target lesions. Target lesions were up to a maximum of 5 per organ \& \>20 mm by clinical imaging (\>=10 mm with spiral CT scan). Non-target lesions were all other lesions. Evaluation of progress was repeated every 3 months (+/-7 days) post first date of lesion measurements, in detection absence until the participant´s death.
| Participants | Pegylated Liposomal Doxorubicin (PLD) | Capecitabine |
|---|---|---|
| By Investigator Assessment - CR | 1 | 0 |
| By Investigator Assessment - PR | 5 | 12 |
| By Investigator Assessment Overall Response | 6 | 12 |
| By RECIST Criteria - CR | 1 | 0 |
| By RECIST Criteria - PR | 8 | 11 |
| By RECIST Criteria Overall Response | 9 | 11 |
Survival time was defined as duration time from onset of treatment with the study drug until death.
| Months | Pegylated Liposomal Doxorubicin (PLD) | Capecitabine |
|---|---|---|
| Overall Survival Time in the PLD and Capecitabine Treatment Groups | 23.31 (21.44 to 27.52) | 26.79 (18.67 to 32.28) |
Time to treatment failure was defined as the duration of time from the date of the first administration of the study drug to the date of discontinuation of the study drug for any reason.
| Months | Pegylated Liposomal Doxorubicin (PLD) | Capecitabine |
|---|---|---|
| Time to Treatment Failure in the PLD and the Capecitabine Treatment Groups | 4.60 (3.35 to 4.93) | 3.68 (2.93 to 5.85) |
QoL questionnaire was an EORTC QLQ-C30 \& SSQ integration. Scores on the SSQ scale ranged from 1 (very much worse) - 7 (very much better). SSQ consisted of 4 items which corresponded to core domains in the 30 Item EORTC QLQ-C30, such as improvement/deterioration in physical functioning, emotional functioning, social functioning, global QoL. Percentages were based on number of participants at each cycle \& rounded to the nearest whole number. Early Withdrawal Questionnaires were obtained in 7-14 days of study drug final dose.
| Percentage of Participants | Pegylated Liposomal Doxorubicin (PLD) | Capecitabine |
|---|---|---|
| Screening - Very Much Worse | 4 | 14 |
| Screening - Moderately Worse | 8 | 14 |
| Screening - A Little Worse | 12 | 24 |
| Screening - About the Same | 67 | 41 |
| Screening - A Little Better | 4 | 0 |
| Screening - Moderately Better | 2 | 0 |
| Screening - Very Much Better | 2 | 7 |
| Cycle 1 - Very Much Worse | 0 | 9 |
| Cycle 1 - Moderately Worse | 10 | 9 |
| Cycle 1 - A Little Worse | 22 | 9 |
| Cycle 1 - About the Same | 63 | 65 |
| Cycle 1 - A Little Better | 5 | 2 |
| Cycle 1 - Moderately Better | 0 | 5 |
| Cycle 1 - Very Much Better | 0 | 0 |
| Cycle 2 - Very Much Worse | 3 | 11 |
| Cycle 2 - Moderately Worse | 9 | 8 |
| Cycle 2 - A Little Worse | 25 | 15 |
| Cycle 2 - About the Same | 51 | 50 |
| Cycle 2 - A Little Better | 9 | 9 |
| Cycle 2 - Moderately Better | 1 | 5 |
| Cycle 2 - Very Much Better | 1 | 3 |
| Cycle 3 - Very Much Worse | 4 | 3 |
| Cycle 3 - Moderately Worse | 13 | 13 |
| Cycle 3 - A Little Worse | 13 | 23 |
| Cycle 3 - About the Same | 58 | 48 |
| Cycle 3 - A Little Better | 8 | 10 |
| Cycle 3 - Moderately Better | 4 | 2 |
| Cycle 3 - Very Much Better | 0 | 0 |
| Cycle 4 - Very Much Worse | 4 | 6 |
| Cycle 4 - Moderately Worse | 11 | 12 |
| Cycle 4 - A Little Worse | 26 | 22 |
| Cycle 4 - About the Same | 47 | 55 |
| Cycle 4 - A Little Better | 9 | 2 |
| Cycle 4 - Moderately Better | 2 | 4 |
| Cycle 4 - Very Much Better | 0 | 0 |
| Cycle 5 - Very Much Worse | 5 | 0 |
| Cycle 5 - Moderately Worse | 0 | 2 |
| Cycle 5 - A Little Worse | 21 | 19 |
| Cycle 5 - About the Same | 40 | 62 |
| Cycle 5 - A Little Better | 19 | 14 |
| Cycle 5 - Moderately Better | 10 | 2 |
| Cycle 5 - Very Much Better | 5 | 0 |
| Cycle 6 - Very Much Worse | 5 | 3 |
| Cycle 6 - Moderately Worse | 7 | 6 |
| Cycle 6 - A Little Worse | 9 | 11 |
| Cycle 6 - About the Same | 58 | 60 |
| Cycle 6 - A Little Better | 14 | 14 |
| Cycle 6 - Moderately Better | 5 | 3 |
| Cycle 6 - Very Much Better | 2 | 3 |
| Cycle 7 - Very Much Worse | 0 | 3 |
| Cycle 7 - Moderately Worse | 4 | 3 |
| Cycle 7 - A Little Worse | 17 | 23 |
| Cycle 7 - About the Same | 52 | 42 |
| Cycle 7 - A Little Better | 13 | 6 |
| Cycle 7 - Moderately Better | 13 | 16 |
| Cycle 7 - Very Much Better | 0 | 6 |
| Cycle 8 - Very Much Worse | 0 | 3 |
| Cycle 8 - Moderately Worse | 13 | 6 |
| Cycle 8 - A Little Worse | 17 | 16 |
| Cycle 8 - About the Same | 57 | 61 |
| Cycle 8 - A Little Better | 9 | 6 |
| Cycle 8 - Moderately Better | 0 | 6 |
| Cycle 8 - Very Much Better | 4 | 0 |
| Cycle 9 - Very Much Worse | 6 | 0 |
| Cycle 9 - Moderately Worse | 0 | 3 |
| Cycle 9 - A Little Worse | 25 | 21 |
| Cycle 9 - About the Same | 50 | 55 |
| Cycle 9 - A Little Better | 6 | 10 |
| Cycle 9 - Moderately Better | 6 | 3 |
| Cycle 9 - Very Much Better | 6 | 7 |
| Cycle 10 - Very Much Worse | 0 | 4 |
| Cycle 10 - Moderately Worse | 8 | 8 |
| Cycle 10 - A Little Worse | 17 | 13 |
| Cycle 10 - About the Same | 67 | 50 |
| Cycle 10 - A Little Better | 8 | 13 |
| Cycle 10 - Moderately Better | 0 | 4 |
| Cycle 10 - Very Much Better | 0 | 8 |
| Cycle 11 - Very Much Worse | 0 | 0 |
| Cycle 11 - Moderately Worse | 11 | 9 |
| Cycle 11 - A Little Worse | 0 | 13 |
| Cycle 11 - About the Same | 67 | 39 |
| Cycle 11 - A Little Better | 11 | 13 |
| Cycle 11 - Moderately Better | 11 | 9 |
| Cycle 11 - Very Much Better | 0 | 17 |
| Cycle 12 - Very Much Worse | 0 | 4 |
| Cycle 12 - Moderately Worse | 0 | 8 |
| Cycle 12 - A Little Worse | 11 | 13 |
| Cycle 12 - About the Same | 78 | 50 |
| Cycle 12 - A Little Better | 11 | 13 |
| Cycle 12 - Moderately Better | 0 | 8 |
| Cycle 12 - Very Much Better | 0 | 4 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegylated Liposomal Doxorubicin (PLD) | — | 30/98 (30.6%) | 96/98 (98%) |
| Capecitabine | — | 46/102 (45.1%) | 98/102 (96.1%) |
| Event | Pegylated Liposomal Doxorubicin (PLD) | Capecitabine |
|---|---|---|
| DIARRHOEAGastrointestinal disorders | 2/98 | 8/102 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 0/98 | 6/102 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 2/98 | 5/102 |
| GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders | 4/98 | 2/102 |
| HAEMOGLOBIN DECREASEDInvestigations | 1/98 | 4/102 |
| PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders | 1/98 | 4/102 |
| DISEASE PROGRESSIONGeneral disorders | 0/98 | 3/102 |
| FATIGUEGeneral disorders | 2/98 | 3/102 |
| PYREXIAGeneral disorders | 0/98 | 3/102 |
| MALIGNANT PLEURAL EFFUSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/98 | 3/102 |
| Event | Pegylated Liposomal Doxorubicin (PLD) | Capecitabine |
|---|---|---|
| PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders | 65/98 | 68/102 |
| FATIGUEGeneral disorders | 53/98 | 54/102 |
| EAR, NOSE AND THROAT EXAMINATION ABNORMALInvestigations | 42/98 | 17/102 |
| NAUSEAGastrointestinal disorders | 41/98 | 41/102 |
| DIARRHOEAGastrointestinal disorders | 14/98 | 42/102 |
| STOMATITISGastrointestinal disorders | 39/98 | 17/102 |
| WHITE BLOOD CELL COUNT DECREASEDInvestigations | 37/98 | 16/102 |
| ALOPECIASkin and subcutaneous tissue disorders | 27/98 | 10/102 |
| VOMITINGGastrointestinal disorders | 18/98 | 28/102 |
| CONSTIPATIONGastrointestinal disorders | 25/98 | 10/102 |
| Age, Continuous(years) | Pegylated Liposomal Doxorubicin (PLD) | Capecitabine | Total |
|---|---|---|---|
| Mean | 61.4 ± 10.66 | 61.5 ± 10.59 | 61.5 ± 10.60 |
| Sex: Female, Male(Participants) | Pegylated Liposomal Doxorubicin (PLD) | Capecitabine | Total |
|---|---|---|---|
| Female | 105 | 105 | 210 |
| Male | 0 | 0 | 0 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Jan 2006 to primary completion in Sep 2010, 56 months.
Results were first posted in Nov 2011, 1 year 1 month after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 56 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal doxorubicin